NHE1-targeted therapy has been proposed as ancillary therapy to overcome the cancer cell metabolic resilience, and indeed, several in vitro studies demonstrated that NHE1 inhibition amplifies the efficiency of chemotherapeutics4–6, and mouse xenografts of NHE1-deficient cancer cell lines showed reduced capacity for growth7,8. The gene discussed is SLC9A1; the disease is cancer.